Over the last two decades, significant advances in understanding the pathogenic mechanisms underpinning psoriasis, have led to the adoption of biological treatments (“biologics”) targeting the key cytokines TNF, IL-23 and IL-17A, which have transformed disease management. The gene discussed is IL17A; the disease is psoriasis.